Jasper Therapeutics (JSPR, Financial) has been on analysts' radar lately. JMP Securities analyst Silvan Tuerkcan gave the stock a "buy" rating and projected it to reach $70.00. The Tuerkcan's optimistic outlook is due to Jasper's progress in its briquilimab program, which is advancing well in Phase III trials.
The randomized clinical trial BEACON Phase 1b/2a is one of Jasper's leading investigative programs. It aims to evaluate briquilimab as a treatment for CSU. Early data from this trial, expected in the first quarter of 2025, suggests that briquilimab may have a unique safety profile compared to other therapies. This targeted approach to c-Kit has demonstrated notable effectiveness in preclinical trials, drawing investor interest.
While Jasper has ceased enrollment and discontinued the LR-MDS program due to limited gains observed in hematopoiesis, management remains confident in Briquilimab's long-term safety profile. The recent Phase Ib/IIa trial, known as SPOTLIGHT, has provided further evidence of briquilimab's efficacy in mast cell-mediated disorders, with participants reporting symptom improvement in cases of chronic urticaria.
Jasper's strong cash position currently supports ongoing and upcoming projects through 2025, further boosting investor confidence. Another analyst from H.C. Wainwright also maintained a Buy rating with a slightly lower target price of $60.00.
Stock fundamentals could potentially drive Jasper upward if analysts and key opinion leaders continue to endorse briquilimab's effectiveness and the company's strategic focus on targeted treatments.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。